These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 24795067)
1. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Fiechtner JJ; Montroy T Lupus; 2014 Aug; 23(9):905-12. PubMed ID: 24795067 [TBL] [Abstract][Full Text] [Related]
2. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod. Petri MA; Martin RS; Scheinberg MA; Furie RA Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505 [TBL] [Abstract][Full Text] [Related]
3. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial. Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus. Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383 [TBL] [Abstract][Full Text] [Related]
5. The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus. Jiang HZ; Lin ZG; Li HJ; -Du Q; -Tian W; Wang SY; Guan SQ; Mei YF Clin Rheumatol; 2018 Jan; 37(1):151-160. PubMed ID: 29168029 [TBL] [Abstract][Full Text] [Related]
6. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial. Lima GL; Paupitz J; Aikawa NE; Takayama L; Bonfa E; Pereira RM Arthritis Care Res (Hoboken); 2016 Jan; 68(1):91-8. PubMed ID: 25988278 [TBL] [Abstract][Full Text] [Related]
7. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial. Jolly M; Annapureddy N; Arnaud L; Devilliers H Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267 [TBL] [Abstract][Full Text] [Related]
8. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227 [TBL] [Abstract][Full Text] [Related]
9. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). Rendas-Baum R; Baranwal N; Joshi AV; Park J; Kosinski M J Patient Rep Outcomes; 2021 Apr; 5(1):33. PubMed ID: 33830377 [TBL] [Abstract][Full Text] [Related]
10. [The application and influence factors of FACIT Fatigue Scale in SLE patients]. Li HJ; Du Q; Wang SY; Guan SQ; Zhan HH; Tian W; Shao YX; Zhang ZY; Mei YF Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(35):2775-2778. PubMed ID: 28954338 [No Abstract] [Full Text] [Related]
11. Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cárdenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Zeña-Huancas PA; Pastor-Asurza CA; Perich-Campos RA; Rodríguez-Bellido ZJ; Alarcón GS; Ugarte-Gil MF Lupus; 2020 Oct; 29(12):1644-1649. PubMed ID: 32741305 [TBL] [Abstract][Full Text] [Related]
12. Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus. Elefante E; Tani C; Stagnaro C; Ferro F; Parma A; Carli L; Signorini V; Zucchi D; Peta U; Santoni A; Raffaelli L; Mosca M RMD Open; 2020 Feb; 6(1):. PubMed ID: 32075876 [TBL] [Abstract][Full Text] [Related]
13. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients. Li X; Golubovsky J; Hui-Yuen J; Shah U; Olech E; Lomeo R; Singh V; Busch H; Strandberg MJ; Strandberg K; Horowitz L; Askanase A F1000Res; 2015; 4():1103. PubMed ID: 27158444 [TBL] [Abstract][Full Text] [Related]
14. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687 [TBL] [Abstract][Full Text] [Related]
15. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA; Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. Ward MM; Marx AS; Barry NN J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805 [TBL] [Abstract][Full Text] [Related]
18. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus. Askanase AD; Furie RA Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860 [TBL] [Abstract][Full Text] [Related]
19. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108 [TBL] [Abstract][Full Text] [Related]
20. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]